Company news
Abbisko Cayman Limited news in 2025
Abbisko Cayman Limited's news releases, calls and decks from 2025, newest first.
Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
December 22, 2025
Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
June 15, 2025
Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT
June 10, 2025
Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC
May 26, 2025
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress
May 12, 2025
2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1
April 27, 2025
Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib
March 31, 2025